Arbutus to Present Imdusiran Data at EASL Congress 2024
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty
Sector Update: Health Care Stocks Softer Friday Afternoon
Health care stocks eased Friday afternoon with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) marginally higher. The iShares Biotechnology ETF (IBB) fell 0.3%.
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
Arbutus Biopharma (ABUS) shareholder Whitefort Capital Management issued an open letter to shareholders Friday urging the company to stop further share issuances and explore strategic alternatives for
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
Asserts Arbutus' Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
The Arbutus Biopharma Corporation (NASDAQ:ABUS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Last week saw the newest quarterly earnings release from Arbutus Biopharma Corporation (NASDAQ:ABUS), an important milestone in the company's journey to build a stronger business. Revenues fell
Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add
Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma with a Buy and maintains $4 price target.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
Earnings Call Summary | Arbutus Biopharma(ABUS.US) Q1 2024 Earnings Conference
The following is a summary of the Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arbutus ended Q1 2024 with cash, cash equivalents, and investments of arou
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
Arbutus Biopharma Announces Chief Scientific Officer's Retirement
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, Vs. Street Est of $3.7M
07:34 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M
Arbutus Biopharma 1Q Loss $17.9M >ABUS
Arbutus Biopharma 1Q Loss $17.9M >ABUS
Press Release: Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: A
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virol
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a